Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Sunday, March 31, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2024 (2024-03-31): 190.14%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
23.42%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Indivior Pharmaceuticals Inc
Market Cap
$4.40B
Return on Equity (ROE)
N/A
TTM Avg
23.42%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.41B
Return on Equity (ROE)
-42.32%
TTM Avg
-13.82%
3Y Avg
-5.11%
5Y Avg
-5.11%
Market Cap
$4.41B
Return on Equity (ROE)
-44.68%
TTM Avg
-52.94%
3Y Avg
-55.51%
5Y Avg
-46.01%
Market Cap
$4.28B
Return on Equity (ROE)
-44.02%
TTM Avg
-30.64%
3Y Avg
-28.05%
5Y Avg
-12.80%
Market Cap
$4.63B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.15B
Return on Equity (ROE)
14.23%
TTM Avg
-7.71%
3Y Avg
-5.30%
5Y Avg
-10.52%
Market Cap
$4.66B
Return on Equity (ROE)
16.63%
TTM Avg
15.37%
3Y Avg
15.09%
5Y Avg
11.91%
Market Cap
$4.66B
Return on Equity (ROE)
-38.51%
TTM Avg
-50.16%
3Y Avg
-65.11%
5Y Avg
-61.13%
Market Cap
$4.68B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indivior Pharmaceuticals Inc (INDV) | $4.40B | N/A | 23.42% | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.41B | -42.32% | -13.82% | -5.11% | -5.11% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | -44.68% | -52.94% | -55.51% | -46.01% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | -44.02% | -30.64% | -28.05% | -12.80% |
| BillionToOne, Inc. (BLLN)vs › | $4.63B | 6.24% | -11.62% | -98.18% | -98.18% |
| LivaNova PLC (LIVN)vs › | $4.15B | 14.23% | -7.71% | -5.30% | -10.52% |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 16.63% | 15.37% | 15.09% | 11.91% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.66B | -38.51% | -50.16% | -65.11% | -61.13% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 3.43% | -1.67% | -7.64% | -9.04% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.08B | -18.38% | -15.28% | -7.60% | -0.19% |
ROE
N/A
ROA
28.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-03-31 | 190.14% |
| 2023-06-30 | -50.43% |
| 2023-03-31 | -69.44% |
| 2022-12-31 | -103.36% |
| 2022-09-30 | 73.13% |
